Supplemental Financial Information

9 Months Ended

Sep. 30, 2024

Supplemental Financial Information [Abstract]

SUPPLEMENTAL FINANCIAL INFORMATION

NOTE 4 - SUPPLEMENTAL FINANCIAL INFORMATION

Accrued Liabilities

Accrued liabilities consisted of the following:

	September 30, 2024		December 31, 2023
Accrued compensation	$	615,452	$	568,689
Accrued research and development expenses		1,377,903		-
Insurance premium financing		-		716,897
	$	1,993,355	$	1,285,586

In October 2023, the Company entered into a short-term note payable of $914,063 for the financing of insurance premiums. The note bore interest at 9.95% and monthly principal and interest payments of $105,819 were paid over a 9-month period. The Company recorded interest expense of $851 and $24,063 related to the short-term note payable during the three and nine months ended September 30, 2024.